CeriBell, Inc./$CBLL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CeriBell, Inc.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
- Ticker
- $CBLL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 327
- Headquarters
- Sunnyvale, United States
- Website
- www.ceribell.com
CeriBell, Inc. Metrics
BasicAdvanced
$1B
-
-$1.76
-
-
Price and volume
Market cap
$1B
52-week high
$28.19
52-week low
$10.85
Average daily volume
452K
Financial strength
Current ratio
9.177
Quick ratio
8.445
Long term debt to equity
0.162
Total debt to equity
0.171
Interest coverage (TTM)
-38.57%
Profitability
EBITDA (TTM)
-68.803
Gross margin (TTM)
88.90%
Net profit margin (TTM)
-64.73%
Operating margin (TTM)
-68.62%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-23.38%
Return on equity (TTM)
-43.93%
Valuation
Price to revenue (TTM)
9.755
Price to book
7.92
Price to tangible book (TTM)
7.92
Price to free cash flow (TTM)
-17.731
Free cash flow yield (TTM)
-5.64%
Free cash flow per share (TTM)
-1.499
Growth
Revenue change (TTM)
31.70%
Earnings per share change (TTM)
-2.78%
What the Analysts think about CeriBell, Inc.
Analyst ratings (Buy, Hold, Sell) for CeriBell, Inc. stock.
Analyst projections of the future price of CeriBell, Inc. stock.
Bulls say / Bears say
Core demand is growing quickly: second-quarter revenue rose 33% year on year, and Ceribell raised its 2026 revenue guidance to $114 million–$117 million. Growth came from new hospital accounts and increased use in existing accounts. (SEC)
The core product still has room to spread: Ceribell had deployed it in more than 700 hospitals by June, against roughly 6,000 US acute-care facilities the company says could benefit. More use in existing hospitals offers another growth lever beyond adding accounts. (SEC)
FDA clearance for new quantitative EEG tools adds brain-activity trending and amplitude-integrated EEG, extending the platform’s potential use across adult and neonatal care. Wider clinical use could support demand beyond seizure monitoring. (GlobeNewswire)
Profitability remains a challenge: second-quarter operating expenses rose 37% while revenue rose 33%, and the net loss widened to $19.3 million from $13.6 million a year earlier. The quarter’s 92% gross margin also included a one-off tariff refund. (SEC)
Ceribell remains cash-consuming: it reported $129.3 million in cash and marketable securities but had an accumulated deficit of $259.4 million and expects near-term losses. It says it may need more capital if cash generation falls short or costs exceed plan, creating potential funding and dilution risk. (SEC)
The newer growth opportunities are not yet proven revenue drivers: management said delirium, paediatric and neonatal products were not expected to contribute materially in 2026, with more meaningful revenue expected in 2027. Slower adoption would leave growth more dependent on the existing seizure business for longer. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
CeriBell, Inc. Financial Performance
Revenues and expenses
CeriBell, Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
CeriBell, Inc. News
AllArticlesVideos
Funds containing CeriBell, Inc.
Fund name | Fund size | $CBLL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.